ライフサイエンスコーパス: capecitabine

1 b-capecitabine, and 269 received trastuzumab-capecitabine).

2 133 underwent chemoradiotherapy (54 Gy plus capecitabine).

3 eiving lapatinib-capecitabine or trastuzumab-capecitabine.

4 rates were 11.0% for eribulin and 11.5% for capecitabine.

5 HFS over the first 6 weeks of treatment with capecitabine.

6 vival with less toxicity than lapatinib plus capecitabine.

7 icin and per-protocol analysis of CMF versus capecitabine.

8 ntly compared with a similar regimen without capecitabine.

9 ent of grade 2 or higher HFS or cessation of capecitabine.

10 odysesthesia were higher with lapatinib plus capecitabine.

11 mab and a taxane, to T-DM1 or lapatinib plus capecitabine.

12 QoL compared with 69 of 123 (56%) receiving capecitabine.

13 reventing HFS symptoms in patients receiving capecitabine.

14 twice per day for 21 days after the start of capecitabine.

15 cil or cyclophosphamide plus doxorubicin) or capecitabine.

16 eive gemcitabine and 364 to gemcitabine plus capecitabine.

17 s) versus 35 days observed was predicted for capecitabine.

18 le with no effect on the pharmacokinetics of capecitabine.

19 cells than plasma from mice treated with LDM capecitabine.

20 apeutic limitations of MTD compared with LDM capecitabine.

21 r prevention of HFS in patients treated with capecitabine.

22 (1,000 mg/m(2) twice daily) or placebo plus capecitabine.

23 etaxel 20 mg/m(2) (intravenous, weekly x 5); capecitabine 1,000 mg/m(2) orally twice daily on days 1

24 LOX, as oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 e

25 for Schedule 2/1 was sunitinib 50 mg/d plus capecitabine 1,000 mg/m(2) twice per day.

26 he CDD schedule was sunitinib 37.5 mg/d plus capecitabine 1,000 mg/m(2) twice per day; the MTD for Sc

27 irubicin 50 mg/m(2), oxaliplatin130 mg/m(2), capecitabine 1,000 mg/m(2)/d + P 9 mg/kg every 3 weeks).

28 rubicin 50 mg/m(2), oxaliplatin 100 mg/m(2), capecitabine 1,000 mg/m(2)/d, and P 9 mg/kg every 3 week

29 hibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m(2) twice daily) or placebo plus

30 ), respectively, x four cycles), followed by capecitabine (1,250 mg/m(2) twice a day on days 1 to 14,

31 to 14) every 21 days followed by concurrent capecitabine (1,330 mg/m(2) per day) and radiotherapy (4

32 0 mg/m(2) intravenously on days 1 and 8) and capecitabine (1,500 mg/m(2) per day on days 1 to 14) eve

33 g/m(2) and oxaliplatin 100 mg/m(2) on day 1, capecitabine 1000 mg/m(2) per day on days 1-21, and pani

34 /kg intravenously every 3 weeks) or control (capecitabine 1000 mg/m(2) self-administered orally twice

35 130 mg/m(2) intravenously over 2 h and oral capecitabine 1000 mg/m(2) twice daily on days 1-14 repea

36 iplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3

37 Treatment consisted of capecitabine (1000 mg/m(2) orally twice a day on days 1-

38 (2) and oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1250 mg/m(2) per day on days 1-21) or modif

39 cycle) or four 3-week cycles of 2500 mg/m(2) capecitabine (1250 mg/m(2) given twice daily on days 1-1

40 sion, and 12 weeks of postoperative adjuvant capecitabine (1250 mg/m2 twice daily for 14 days every 3

41 tin [60 mg/m(2)] intravenously on day 1, and capecitabine [1250 mg/m(2)] daily throughout the four cy

42 ib-capecitabine (lapatinib 1,250 mg per day; capecitabine 2,000 mg/m(2) per day on days 1 to 14 every

43 wed by an infusion of 6 mg/kg every 3 weeks; capecitabine 2,500 mg/m(2) per day on days 1 to 14 every

44 one (40 mg/m(2) intravenously on day 1) plus capecitabine (2,000 mg/m(2) orally on days 1 through 14)

45 zed phase III trial comparing sunitinib plus capecitabine (2,000 mg/m2) with single-agent capecitabin

46 capecitabine (2,000 mg/m2) with single-agent capecitabine (2,500 mg/m2) in patients with heavily pret

47 enously; cisplatin 60 mg/m(2) intravenously; capecitabine 625 mg/m(2) orally twice daily) in 21-day c

48 cisplatin 60 mg/m(2) intravenously on day 1, capecitabine 625 mg/m(2) twice a day orally on days 1-21

49 onsisted of cisplatin 60 mg/m(2) (day 1) and capecitabine 625 mg/m(2) twice daily (days 1-21) for fou

50 taxel (75 mg per square meter on day 1) plus capecitabine (825 mg per square meter twice a day on day

51 cetaxel alone (100 mg/m(2)) with addition of capecitabine (825 mg/m(2) oral twice daily days 1-14, 75

52 Enrolled patients received capecitabine (825 mg/m(2) orally twice daily) with radio

53 0 mg/m(2) once per week for 5 weeks) or oral capecitabine (825 mg/m(2) twice per day, 5 days per week

54 0.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pan

55 chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily), total mesorectal e

56 Capecitabine (825, 1,000, or 1,250 mg/m(2)) was administ

57 ravenous infusion, at days 1, 8, and 15) and capecitabine (830 mg/m(2) orally twice daily for 21 days

58 r gemcitabine (300 mg/m(2) once per week) or capecitabine (830 mg/m(2) twice daily, Monday to Friday

59 m(2) on days 1, 8, 15 of a 28-day cycle] and capecitabine [830 mg/m(2) twice daily on days 1-21 of a

60 (PFS); and substitution of fluorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change f

61 efore random assignment, investigators chose capecitabine, a taxane (paclitaxel, nab-paclitaxel, or d

62 Addition of ixabepilone to capecitabine adds approximately $31,000 to overall medic

63 weeks (one cycle) or with 1660 mg/m(2) oral capecitabine administered for 21 days followed by 7 days

64 Capecitabine administration with docetaxel, epirubicin,

65 e combination chemotherapy (oxaliplatin plus capecitabine) after the diagnosis of new liver and lung

66 (1:1) to receive eight 3-week cycles of oral capecitabine alone (1250 mg/m(2) twice daily for 14 days

67 ,000 mg/m(2) orally on days 1 through 14) or capecitabine alone (2,500 mg/m(2) on the same schedule)

68 with bevacizumab and capecitabine than with capecitabine alone (median 9.1 months [95% CI 7.3-11.4]

69 rious adverse events were reported (221 with capecitabine alone and 350 with capecitabine and bevaciz

70 as being related to treatment, eight in the capecitabine alone group and 15 in the capecitabine and

71 of whom 1941 had assessable data (968 in the capecitabine alone group and 973 in the capecitabine and

72 hand-foot syndrome (201 [21%] of 963 in the capecitabine alone group vs 257 [27%] of 959 in the cape

73 bevacizumab group vs 78.4%, 75.7-80.9 in the capecitabine alone group; hazard ratio 1.06, 95% CI 0.89

74 bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic c

75 improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast ca

76 ness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metast

77 ilone-capecitabine combination compared with capecitabine alone, although this did not result in impr

78 ecitabine and $30,000 for patients receiving capecitabine alone.

79 otential benefit of systemic oxaliplatin and capecitabine alternating with HAI of FUDR.

80 ,900 for patients receiving ixabepilone plus capecitabine and $30,000 for patients receiving capecita

81 afety and tolerability of the combination of capecitabine and (131)I-huA33.

82 tuzumab emtansine, 254 (51%) of 495 received capecitabine and 241 [49%] of 495 received lapatinib (se

83 was 3% (eight of 251 patients) for lapatinib-capecitabine and 5% (12 of 250 patients) for trastuzumab

84 n the groups (75.4%, 95% CI 72.5-78.0 in the capecitabine and bevacizumab group vs 78.4%, 75.7-80.9 i

85 abine alone group vs 257 [27%] of 959 in the capecitabine and bevacizumab group) and diarrhoea (102 [

86 the capecitabine alone group and 973 in the capecitabine and bevacizumab group).

87 n the capecitabine alone group and 15 in the capecitabine and bevacizumab group.

88 ed (221 with capecitabine alone and 350 with capecitabine and bevacizumab).

89 We investigated whether capecitabine and docetaxel followed by fluorouracil, epi

90 istributions in the phase III study for both capecitabine and FU were consistent with observed values

91 Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve

92 Both capecitabine and gemcitabine were associated with increa

93 d to either trastuzumab emtansine (n=495) or capecitabine and lapatinib (control; n=496).

94 al fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or with

95 Patients received 12 weeks of neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on d

96 rm efficacy of neoadjuvant chemotherapy with capecitabine and oxaliplatin before chemoradiotherapy an

97 CLUSION Alternating HAI of FUDR and systemic capecitabine and oxaliplatin met the prespecified end po

98 APOX50 (50-Gy RT for 5 weeks with concurrent capecitabine and oxaliplatin).

99 e cell cycle phase-specific cytotoxic drugs, capecitabine and paclitaxel.

100 TR) = 1.26, 95% CI: 1.02-1.57, P = 0.035) or capecitabine and radiation (TR = 1.25, 95% CI: 1.04-1.51

101 INTERPRETATION: Veliparib plus capecitabine and radiotherapy had an acceptable safety p

102 d recommended phase 2 dose of veliparib plus capecitabine and radiotherapy, with an exposure-adjusted

103 dose of veliparib combined with neoadjuvant capecitabine and radiotherapy.

104 f 267 patients) of patients in the lapatinib-capecitabine and trastuzumab-capecitabine arms, respecti

105 no difference was detected between lapatinb-capecitabine and trastuzumab-capecitabine for the incide

106 The addition of vemurafenib to capecitabine and/or bevacizumab, cetuximab and/or irinot

107 treated with an anthracycline, a taxane, and capecitabine (and two to five previous regimens for adva

108 40 enrolled patients (271 received lapatinib-capecitabine, and 269 received trastuzumab-capecitabine)

109 treated with the combination of bevacizumab, capecitabine, and radiation.

110 mab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in pat

111 therapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned t

112 (95% CI, 4.5 to 6.0) for the sunitinib plus capecitabine arm and 5.9 months (95% CI, 5.4 to 7.6) for

113 versus 401 days observed for survival in the capecitabine arm.

114 n the lapatinib-capecitabine and trastuzumab-capecitabine arms, respectively.

115 We tested for the noninferiority of capecitabine as compared with standard chemotherapy in w

116 ere randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line che

117 c toxicity decreased (P = .008), whereas for capecitabine, as CrCl increased, the odds of experiencin

118 included oxaliplatin 130 mg/m(2) day 1 with capecitabine at 1,000 mg/m(2) twice daily, days 1 throug

119 fractions over 5 weeks with concurrent oral capecitabine at 650 mg/m(2) twice per day continuously d

120 nd feasibility of both gemcitabine-based and capecitabine-based chemoradiotherapy after induction che

121 Our results suggest that a capecitabine-based regimen might be preferable to a gemc

122 n and fluorouracil, and was also similar for capecitabine-based regimens versus leucovorin and fluoro

123 nitoring system (MEMS) caps on participants' capecitabine bottles to record pill bottle openings.

124 ion, for which gemcitabine, fluorouracil, or capecitabine can be used as concurrent chemotherapy agen

125 ugs containing both camptothecin (CPT) and a capecitabine (Cap) analogue.

126 plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorecta

127 Capecitabine (CAP) is a 5-FU pro-drug approved for the t

128 efore random assignment, investigators chose capecitabine (Cape; 2,000 mg/m(2) for 14 days), taxane (

129 cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel

130 After 12 weeks of induction gemcitabine and capecitabine chemotherapy (three cycles of gemcitabine [

131 o receive a further cycle of gemcitabine and capecitabine chemotherapy followed by either gemcitabine

132 0 patients scheduled to receive single-agent capecitabine chemotherapy for breast, colorectal, and ot

133 th peri-operative epiribicin, cisplatin, and capecitabine chemotherapy for patients with resectable g

134 ve peri-operative epirubicin, cisplatin, and capecitabine chemotherapy or chemotherapy plus bevacizum

135 erative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m(2) epirubicin and 60

136 mproved PFS and response for the ixabepilone-capecitabine combination compared with capecitabine alon

137 the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly

138 e the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for r

139 alent relapse-free and overall survival with capecitabine compared with standard chemotherapy.

140 able survival outcomes when treated with the capecitabine-containing regimen in an exploratory subgro

141 However, capecitabine could be used in place of CMF without signi

142 Replacement of fluorouracil with capecitabine did not improve global QoL: 69 of 124 (56%)

143 Capecitabine did not improve QoL compared with fluoroura

144 nd safety of gemcitabine-docetaxel (GD) with capecitabine-docetaxel (CD) in advanced breast cancer.

145 The addition of sunitinib to capecitabine does not improve the clinical outcome of pa

146 t of HFS greater than grade 1, evaluation of capecitabine dose intensity, and quality of life analyse

147 Capecitabine dose intensity, time under study, and perce

148 Sunitinib and capecitabine doses were escalated in serial patient coho

149 mab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or

150 or four cycles of epirubicin, cisplatin, and capecitabine (ECX; four 3-weekly cycles of epirubicin [5

151 However, lapatinib-capecitabine efficacy may have been affected by previous

152 panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagoga

153 Epirubicin, oxaliplatin, and capecitabine (EOC) is a standard treatment in advanced e

154 capecitabine); leucovorin and fluorouracil; capecitabine; FOLFOX-4 (leucovorin, fluorouracil, and ox

155 her half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, e

156 ent due to vascular disorder (docetaxel plus capecitabine followed by doxorubicin plus cyclophosphami

157 phamide group), sudden death (docetaxel plus capecitabine followed by doxorubicin plus cyclophosphami

158 lled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human ep

159 lowed dosing adjustments of methotrexate and capecitabine for pretreatment renal function.

160 etween lapatinb-capecitabine and trastuzumab-capecitabine for the incidence of CNS metastases.

161 yndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatme

162 inotecan) and ECX (epirubicin, cisplatin,and capecitabine) for AGC from the cost-effectiveness perspe

163 s randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP).

164 cancer-specific survival tended to favor the capecitabine group (HR, 0.79; 95% CI, 0.60-1.04; P = .10

165 al was 12.0 months (95% CI 10.2-14.6) in the capecitabine group and 10.4 months (95% CI 8.9-12.5) in

166 al was 15.2 months (95% CI 13.9-19.2) in the capecitabine group and 13.4 months (95% CI 11.0-15.7) in

167 le patients (62.9%, 80% CI 50.6-73.9) in the capecitabine group and 18 of 35 assessable patients (51.

168 survival was 79.2% (95% CI 61.1-89.5) in the capecitabine group and 64.2 (95% CI 46.4-77.5) in the ge

169 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse e

170 Two patients in the capecitabine group died of treatment-related complicatio

171 Eight patients in the capecitabine group had an objective response at 26 weeks

172 atients in the gemcitabine group than in the capecitabine group had grade 3-4 haematological toxic ef

173 Two patients in the capecitabine group progressed during the fourth cycle of

174 rate of relapse-free survival was 68% in the capecitabine group versus 85% in the standard-chemothera

175 ratio for disease recurrence or death in the capecitabine group was 2.09 (95% confidence interval, 1.

176 urvival for patients in the gemcitabine plus capecitabine group was 28.0 months (95% CI 23.5-31.5) co

177 Of the 34 patients in the capecitabine group who received chemoradiotherapy, 25 (7

178 d (38 to the gemcitabine group and 36 to the capecitabine group).

179 in the combination group and 30 (22%) in the capecitabine group, and treatment-related serious advers

180 nts in the combination group and four in the capecitabine group.

181 A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine

182 ; capecitabine (group C); or oxaliplatin and capecitabine (group D).

183 nts free from TTR events between the CMF and capecitabine groups (HR 0.98, 95% CI 0.85-1.14; stratifi

184 y more patients taking CMF than those taking capecitabine had clinically relevant worsening of qualit

185 chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function

186 chanistic synergy between nab-paclitaxel and capecitabine has been cited as the rationale to combine

187 Oxaliplatin combined with capecitabine has demonstrated activity in advanced color

188 th trastuzumab-capecitabine versus lapatinib-capecitabine (hazard ratio [HR] for PFS, 1.30; 95% CI, 1

189 T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from

190 whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared wit

191 Addition of sorafenib to capecitabine improved PFS in patients with HER2-negative

192 The addition of oxaliplatin to capecitabine improves DFS in patients with stage III col

193 e adherence among women randomly assigned to capecitabine in a preplanned substudy of a multicenter c

194 n and fluorouracil versus those who received capecitabine in adjusted analyses (hazard ratio [HR] 1.0

195 a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in

196 etuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with

197 Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survi

198 d chemotherapy versus oral chemotherapy with capecitabine in patients age 65 years or older with earl

199 or activity of sunitinib in combination with capecitabine in patients with advanced solid tumors.

200 tandard adjuvant chemotherapy is superior to capecitabine in patients with early-stage breast cancer

201 vival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced bre

202 III randomized trial compared eribulin with capecitabine in patients with locally advanced or metast

203 The addition of bevacizumab to capecitabine in the adjuvant setting for colorectal canc

204 better outcome was observed with trastuzumab-capecitabine in the overall population.

205 /methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age >/= 65 wit

206 ur recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-in

207 vant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel

208 Integration of capecitabine into a regimen that contains docetaxel, epi

209 It is not known whether integration of capecitabine into an adjuvant regimen that contains a ta

210 Capecitabine is an active agent in the treatment of brea

211 Capecitabine is an active drug in metastatic breast canc

212 The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen

213 Capecitabine is not considered a standard agent in the a

214 The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for

215 randomly assigned (1:1) to receive lapatinib-capecitabine (lapatinib 1,250 mg per day; capecitabine 2

216 in our analyses were: XELOX (oxaliplatin and capecitabine); leucovorin and fluorouracil; capecitabine

217 evaluation of sunitinib in combination with capecitabine may be undertaken using the MTD for any of

218 and 5.9 months (95% CI, 5.4 to 7.6) for the capecitabine monotherapy arm (hazard ratio, 1.22; 95% CI

219 difference in OS between the combination and capecitabine monotherapy arm, the primary end point (med

220 A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently compri

221 Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respec

222 assigned to receive either bevacizumab plus capecitabine (n=140) or capecitabine only (n=140).

223 Neither capecitabine nor gemcitabine increased disease-free surv

224 men comprised of oxaliplatin, docetaxel, and capecitabine (ODC) combined with radiation therapy (RT).

225 In univariate analysis, the starting dose of capecitabine (odds ratio [OR], 1.99; 95% CI, 1.32-3.00;

226 (2) cisplatin on day 1 and 1250 mg/m(2) oral capecitabine on days 1-21.

227 To investigate the effect of capecitabine on long-term survival outcomes of patients

228 her bevacizumab plus capecitabine (n=140) or capecitabine only (n=140).

229 at precludes other regimens; the addition of capecitabine or erlotinib may be offered.

230 3 x 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by dox

231 The addition of capecitabine or gemcitabine to docetaxel therapy, as com

232 al were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy

233 The choice of fluoropyrimidine therapy (capecitabine or infused fluouroracil plus leucovorin) wa

234 the existing evidence that oxaliplatin plus capecitabine or leucovorin and fluorouracil is the stand

235 of whether the fluoropyrimidine backbone was capecitabine or leucovorin and fluorouracil.

236 metastatic breast cancer receiving lapatinib-capecitabine or trastuzumab-capecitabine.

237 CAP45 (45-Gy RT for 5 weeks with concurrent capecitabine) or CAPOX50 (50-Gy RT for 5 weeks with conc

238 reated with fluoropyrimidines (fluorouracil, capecitabine, or tegafur-uracil as single agents, in com

239 Neoadjuvant chemoradiotherapy consisted of capecitabine (original dose 825 mg/m(2) twice daily on d

240 d the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP

241 T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all additional secon

242 cs were dose proportional, with no effect on capecitabine pharmacokinetics.

243 urvival in a phase III trial on the basis of capecitabine phase II data in CRC.

244 ) or placebo plus epirubicin, cisplatin, and capecitabine (placebo group; n=305).

245 reak for 7 days) or the same regimen of oral capecitabine plus 16 cycles of 7.5 mg/kg bevacizumab by

246 zumab emtansine (233 [48%] of 490) than with capecitabine plus lapatinib control treatment (291 [60%]

247 safety population (488 patients treated with capecitabine plus lapatinib, 490 patients treated with t

248 This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorou

249 aging were identified between the CVI FU and capecitabine regimens or between the two regimens with o

250 osphamide/methotrexate/fluorouracil, AC, and capecitabine, respectively.

251 The addition of sorafenib to capecitabine resulted in a significant improvement in PF

252 The combination of sunitinib and capecitabine resulted in an acceptable safety profile in

253 rilotumumab plus epirubicin, cisplatin, and capecitabine (rilotumumab group; n=304) or placebo plus

254 The adjuvant combination of gemcitabine and capecitabine should be the new standard of care followin

255 as significantly longer with bevacizumab and capecitabine than with capecitabine alone (median 9.1 mo

256 s 70/221 [32%]; p=0.17), but was higher with capecitabine than with fluorouracil (88/222 [40%] vs 65/

257 val and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or

258 verse events were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).

259 represented by the p.o. administered prodrug capecitabine, the gene silencing inhibitor zebularine, a

260 we characterized the effects of LDM and MTD capecitabine therapy on tumor and host cells using high-

261 the probability that, with longer follow-up, capecitabine therapy was highly likely to be inferior to

262 this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epiru

263 89 years); 124 patients (83%) persisted with capecitabine to completion of planned protocol therapy.

264 The addition of gemcitabine or capecitabine to neoadjuvant docetaxel plus doxorubicin p

265 used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colo

266 Global capecitabine toxicity (grades 0/1/2 v grades 3/4/5) was

267 n days 1 to 14 every 21 days) or trastuzumab-capecitabine (trastuzumab loading dose of 8 mg/kg follow

268 Plasma from MTD capecitabine-treated mice induced a more tumorigenic and

269 n NK and T cytotoxic cells were found in MTD-capecitabine-treated tumors compared with LDM-capecitbin

270 Capecitabine treatment was associated with less nausea,

271 uality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better

272 stratified by geographical region, previous capecitabine treatment, and human epidermal growth facto

273 syndrome (HFS) is a common adverse effect of capecitabine treatment.

274 and 5% (12 of 250 patients) for trastuzumab-capecitabine (treatment differences, -1.6%; 95% CI, -2%

275 cations; as compared with patients receiving capecitabine, twice as many patients receiving standard

276 receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosp

277 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX).

278 d the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with

279 nt phase III study (n = 1,000 replicates) of capecitabine versus FU in CRC.

280 PFS and OS were longer with trastuzumab-capecitabine versus lapatinib-capecitabine (hazard ratio

281 Although capecitabine was associated with better QoL during treat

282 y a single-therapy infusion 1 wk later, when capecitabine was commenced.

283 Ruxolitinib plus capecitabine was generally well tolerated and may improv

284 Capecitabine was given in two divided daily doses for 14

285 ease, where the therapeutic advantage of MTD capecitabine was limited despite a substantial initial a

286 d adjuvant chemotherapy with oxaliplatin and capecitabine was recommended.

287 events during chemoradiotherapy, the dose of capecitabine was reduced to 725 mg/m(2) twice-daily, 5 d

288 Capecitabine was reduced to 850 mg/m(2) twice daily afte

289 Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR,

290 with GI tumors or breast cancer treated with capecitabine were included in this randomized phase III

291 Patients who were randomly assigned to capecitabine were twice as likely to have a relapse and

292 ceived RCT (45 to 50 Gy with fluorouracil or capecitabine) were included.

293 nation chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluab

294 lapse survival was also compared between the capecitabine with or without oxaliplatin and leucovorin

295 ival between the patient groups who received capecitabine with or without oxaliplatin and those who r

296 Adjuvant capecitabine with or without oxaliplatin versus leucovor

297 Administering capecitabine with preoperative RT achieved similar rates

298 dy, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.

299 r placebo daily for a maximum of 8 cycles of capecitabine, with stratification by sex and use in adju

300 uzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for h